Evidence map›Paper›PMID 41575699›Full record

ArticleScience China. Life sciences2026

PRR11 as a newly identified oncogenic driver in retinoblastoma.

Yu He, Xueming Ju, Huan Li, Mingze Li, Dan Zhang, Jialing Xiao, Yixiao Wu, Pu Zhang, Zhenglin Yang, Bo Gong

Abstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yu He *School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Xueming Ju *School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Huan Li *School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Mingze Li *School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Dan ZhangSichuan Provincial People's Hospital, Department of Laboratory Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Jialing XiaoSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Yixiao WuSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Pu ZhangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Zhenglin YangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China. yangzhenglin@cashq.ac.cn.
Bo GongSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China. gongbo@med.uestc.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinoblastoma (RB) is the most common pediatric intraocular malignancy and seriously threatens vision and survival if not treated early. However, effective targeted therapies remain unavailable owing to the lack of well-defined molecular targets beyond RB1 gene mutations. There is a critical need to identify novel therapeutic targets. Through transcriptomic analysis of four RB-related datasets (GSE125903, GSE110811, GSE97508, and GSE24673) from the Gene Expression Omnibus (GEO) database, we identified proline-rich 11 (PRR11) as a significantly overexpressed gene in RB. Single-cell transcriptomic analysis revealed that PRR11 exhibits heterogeneous expression in different RB cell types, at particularly high levels in tumor-related populations such as cone precursor-like cells and MKI67

Indexed as

ProteinsRetinal NeoplasmsRetinoblastomaAnimalsCell Line, TumorCell ProliferationGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiceOncogenesWnt Signaling PathwayProteinsPRR11 protein, humancell cycleDKK3OTUB1PRR11retinoblastomaWnt/β-catenin signaling

Identifiers

PMID41575699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.